Business Wire

Yandex injects 600G wavelengths into DCI network with ADVA TeraFlex™

5.11.2020 11:00:00 EET | Business Wire | Press release

Share

ADVA (FSE: ADV) today announced that Yandex has transformed its data center interconnect (DCI) infrastructure into a 600Gbit/s transport network using the ADVA FSP 3000 TeraFlex™. The solution massively increases the capacity of Yandex’s infrastructure throughout Moscow, enabling Russia’s largest search engine provider to meet rapidly rising data demands and expand its cloud services. Delivering high levels of throughput, density and scale, the technology easily plugged into Yandex’s existing line system. ADVA’s open TeraFlex™ terminal supports 600Gbit/s over a single wavelength and delivers a total duplex capacity of 3.6Tbit/s in one rack unit. With its low power consumption and ultra-flexible modulation capabilities, TeraFlex™ ensures maximum spectral efficiency, making Yandex’s DCI network future-proof and highly efficient.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201105005031/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

ADVA's TeraFlex™ technology is helping Yandex to easily scale its DCI network (Photo: Business Wire)

“We’re proud of what our FSP 3000 TeraFlex™ technology is helping Yandex achieve. Without the effort or expense of a complete system upgrade, it’s enabled one of Russia’s biggest technology companies to transform its infrastructure. By unlocking the full value of its fiber assets, Yandex is opening the door to further growth and innovation,” commented Hartmut Müller-Leitloff, SVP, sales, EMEA, ADVA. “Our TeraFlex™ has a large degree of configuration flexibility, using different modulation formats and software-defined fractional QAM to optimize data rate transmission performance. Together with its plug-and-play simplicity, TeraFlex™ made it easy for Yandex to transform its existing DCI infrastructure.”

Yandex’s Moscow data centers are now connected in a point-to-point network with ADVA’s high-density TeraFlex™ terminal. Serving 36 bidirectional 100GbE client ports, the 1RU solution injects new levels of channel capacity and spectral efficiency into Yandex’s network. Built specifically to maximize fiber utilization, TeraFlex™ features software-defined fractional QAM modulation capabilities. This enables it to leverage different modulation formats and optimize all optical paths over any distance.

“We’re helping Yandex to massively expand the capacity of its network and accommodate ever-increasing traffic demands. Our TeraFlex™ terminal is ensuring that one of Russia’s leading technology companies can meet its customers’ expectations and continue growing its business well into the future,” said Stephan Rettenberger, SVP, marketing and investor relations, ADVA. “Tens of millions of people rely on Yandex’s products and services on a daily basis. That’s why it’s a company keen to deliver even more by leveraging the most advanced technology on the market. Our solution enables it to continue innovating and improving quality. And, with the space- and power-efficiency of TeraFlex™, Yandex’s new network also ensures that future growth is fully sustainable.”


About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com

For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release

Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release

Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye